Latest news with #Trially
Business Wire
24-06-2025
- Business
- Business Wire
Trially AI Taps Serial Entrepreneur Christian Smith as CRO to Expand AI Clinical Trial Enrollment Across U.S.
KANSAS CITY, Mo.--(BUSINESS WIRE)-- Trially®, a breakthrough AI clinical trial recruitment technology to unlock faster qualified patient enrollment, today announced the appointment of as Chief Revenue Officer. A serial entrepreneur and proven operator, Smith brings a track record of scaling quality service for healthcare organizations and will lead efforts to accelerate trial enrollment for U.S. site networks, healthcare systems, and sponsors with Trially's AI tools. When my mom passed away of breast cancer in 2005, we had no clue there were 28 studies running within driving distance, including studies for Trastuzumab and Bevacizumab which represent some of the top treatments on the market today. Smith joins Trially at a pivotal moment. As clinical research sites face mounting enrollment pressure and shrinking pipelines, Trially has emerged as a category-defining technology. In a landscape where 68% of sites miss enrollment targets and screen failure rates continue to rise, Trially AI is enabling sites to predictably prescreen and qualify patients for trials — with or without an EHR integration — helping teams multiply enrollment for even the most complex protocols in record time. 'In my late teens, I found how difficult it is to navigate medical care when standard treatment paths do not yield results,' said Smith. 'When my mom passed away of breast cancer in 2005, we had no clue there were 28 studies running within driving distance, including studies for Trastuzumab and Bevacizumab which represent some of the top treatments on the market today. It is an honor to join Trially to serve the physician networks and sites by matching patients with novel drug therapies to improve health outcomes and the standard of care.' Prior to Trially, Smith co-founded TrackR, where he helped create the Bluetooth tracking category and grew revenue to over $50 million. During the COVID-19 pandemic, he led direct-to-consumer operations at Dascena, opening 44 testing sites across 26 cities. Most recently, he co-founded Forta, where he pioneered a family centric autism therapy model powered by AI. His expertise in direct-to-patient recruitment, AI-driven care models, and scaling operational quality — are critical to best support Trially partners. 'Christian brings the exact mindset we value at Trially: efficiency, transparency, empathy,' said Trevor Welch, Co-founder and Chief Product Officer of Trially. "He understands what it means to scale with purpose, and he's passionate about empowering research teams to help patients get access to life-saving therapies. His arrival marks a new chapter in our mission to unlock faster qualified patient enrollment across the industry.' About Trially Trially® is shaping the future of clinical trial recruitment with its proprietary AI matching technology that safely unlocks rich clinical data to enroll qualified patients faster. Proven to multiply enrollment rates by 200%, dramatically reduce screen failures and improve site efficiency, Trially's site-based software rapidly integrates with any EHR or CTMS system while maintaining full compliance with HIPAA, SOC 2, FDA 21 CFR Part 11 and ISO 27001 regulations. Designed to meet the needs of physicians, research sites and pharmaceutical sponsors, Trially empowers you to achieve outstanding results in clinical research. For more information visit
Business Wire
13-05-2025
- Business
- Business Wire
ClinTrial Research Teams Up With Trially AI to Multiply Enrollment in Complex Clinical Trials
RESEARCH TRIANGLE PARK, N.C. & KANSAS CITY, Mo.--(BUSINESS WIRE)-- ClinTrial Research (CTR), a leading site management organization (SMO), today announced a strategic partnership with Trially®, the latest breakthrough in HIPAA-compliant AI matching technology. After six months of collaboration, the partnership has shown significant improvements in patient identification, enrollment speed, and operational efficiency. "Trially's proprietary AI has improved our ability to pre-screen candidates, reducing the time and resources typically spent on manual EHR chart reviews while improving the diversity and quality of our patient pools." Share How Native AI Technology is Advancing Site Operations By implementing Trially's AI EMR matching technology, CTR has experienced notable improvements in its clinical trial operations: Increased monthly patient enrollment rates Significant reduction in screen failures Less time spent on manual EHR chart reviews Increased site revenue due to higher study KPIs Enhanced diversity through real-time protocol population analytics Instant API integrations with multiple EHR systems including IMS, TriMed, Athena, RelyMed, and others Expanded site network capabilities, with successful implementations across multiple therapy areas including Behavioral Health and CNS, Respiratory, Internal Medicine Gastrointestinal, Nephrology and Ophthalmology "Our mission at CTR is to build the premier, next-generation site management organization, setting new standards of excellence in clinical trial management," said ClinTrial Research's Chief Commercial Officer, Sam Searcy. "Our partnership with Trially aligns perfectly with our commitment to using AI-driven data analytics and high-precision patient identification to accelerate clinical trial timelines. Trially's proprietary AI has improved our ability to pre-screen candidates, reducing the time and resources typically spent on manual EHR chart reviews while improving the diversity and quality of our patient pools." Setting New Standards for AI Clinical Trial Enrollment The partnership demonstrates CTR's commitment to setting new standards of excellence in clinical trial management and represents a significant step forward in Trially's mission to get life-saving therapies to patients faster. Both organizations share a vision of accelerating the development of new treatments through more efficient, transparent, and inclusive clinical trials. "We built Trially to solve the root causes of clinical trial delays," said Trially CEO Kyle McAllister. "The team at CTR has done an amazing job integrating our technology into their workflow. Their network of clinical partners really knows how to put our platform to work, making it their top source for finding qualified patients. What impresses me most is how CTR balances technological efficiency with their unwavering commitment to patient care and data security. It's been rewarding to see how they've adapted our solution across different systems to accelerate their enrollment timelines." For more information about the partnership, visit About Trially Trially® is shaping the future of clinical trial recruitment with its proprietary AI matching technology that safely unlocks rich clinical data to enroll qualified patients faster. Proven to multiply enrollment rates by 200%, reduce screen failures by 73%, and improve site efficiency by 90%, Trially's site-based software rapidly integrates with any EMR or CRM while maintaining full compliance with HIPAA, SOC 2, FDA 21 CFR Part 11 and ISO 27001 regulations. Designed to meet the needs of Physicians, Research Sites, Sponsors and CROs, Trially empowers you to achieve outstanding results in clinical research. For more information visit About ClinTrial Research ClinTrial Research (CTR) is a next-generation SMO deploying innovative technology, driving positive physician and patient-centered clinical excellence, while providing high-quality data analytics to Sponsors and CRO partners. CTR is Empowering Research, Enhancing Lives.
